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a b s t r a c t
Male patient in dilated phase of hypertrophic cardiomyopathy hadmultiple hospitalizations
during the past 2 years either due to congestive heart failure, stroke, scar epilepsy, or atrial
ﬁbrillation and ventricular tachycardia. Medication included evidence based therapy for
heart failure, cordarone andwarfarin. Anticoagulation had to be discontinued due tomarked
ﬂuctuations in INR. Transthoracic Echocardiography (TTE) revealed amobilemass in the left
ventricle. He was treated with Dabigatran 110 mg twice a day for 4 months without any
bleeding or embolic episode and complete resolution of thrombus.
Dabigatran is a reversible direct thrombin inhibitor and currently approved for the preven-
tion of thromboembolic episodes in non-valvar atrial ﬁbrillation. This case demonstrates
possible thrombolytic properties of dabigatran in resolution of left ventricular thrombus.
ogical Society of India. Published by Elsevier B.V. All rights reserved.# 2015 CardiolA 61-year-old male patient in dilated phase of hypertrophic
cardiomyopathy hadmultiple hospitalizations during the past
2 years either due to congestive heart failure, stroke, scar
epilepsy, or atrial ﬁbrillation and ventricular tachycardia. He
also had diabetes mellitus and hypertension. The 'CHADS2'
score was 5. His creatinine clearance was 71.31 ml/min.
Medication included ramipril, carvedilol, furosemide, aldac-
tone, cordarone, warfarin, phenytoin sodium, and insulin.
Anticoagulation had to be discontinued due to marked
ﬂuctuations in International Normalized Ratio (INR). Cordar-
one and phenytoin would have contributed to the INR
variations. During recent hospitalization for aggravation of
heart failure, chest X-ray demonstrated cardiomegaly and
pulmonary congestion. Transthoracic Echocardiography (TTE)* Corresponding author at: C/O Dr. Satyavan Sharma, Room no. 104, 1s
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0019-4832/# 2015 Cardiological Society of India. Published by Elsevierrevealed a mobile mass measuring 2.30  1.16 cm2 in the left
ventricle (Panel A, video 1). He was treated with Dabigatran
110 mg twice a day for the past 4monthswithout any bleeding
or embolic episode and resulted in complete resolution of
thrombus (Panel B, video 2) (Fig. 1).
Dabigatran is a reversible direct thrombin inhibitor and is
currently approved for the prevention of thromboembolic
episodes in non-valvar atrial ﬁbrillation1 and in those
undergoing orthopedic surgery.2 The effects of novel oral
anticoagulants on intracardiac thrombi have not been eluci-
dated. There are scattered reports of their use in left atrial
thrombus with variable response ranging from increase in its
size to resolution of clot.3,4 Its potential to inhibit thrombin
bound to ﬁbrin and ﬁbrin degradation products might bet Floor, New Wing, Bombay Hospital, New Marine Lines, Mumbai,
3.
B.V. All rights reserved.
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Fig. 1 – Transthoracic Echocardiography images; Panel A: mobile thrombus 2.3  1.16 cm2 in left ventricle; Panel B: complete
resolution of thrombus after treatment with Dabigatran.
i n d i a n h e a r t j o u r n a l 6 7 ( 2 0 1 5 ) 4 9 5 – 4 9 6496responsible for thrombolysis in this patient. As an alternate
hypothesis, possibility of spontaneous clot lysis cannot be
excluded. The short (4 months) follow-up in this case
demonstrates possible thrombolytic properties of Dabigatran
in resolution of left ventricular thrombus. This observation
needs to be conﬁrmed by larger and long-term data.
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